C4 Therapeutics (United States)

company in Watertown, United States

CCCC Nasdaq SEC CIK 1662579
Follow C4 Therapeutics (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $8.5M −24.6% vs same quarter last year
Net income −$21.8M +32.1% vs same quarter last year
EPS, diluted −$0.16 +63.6% vs same quarter last year
Operating cash flow −$26M +16.8% vs same quarter last year
Revenue by quarter
$5.2M
$7.2M
$6.5M
$11.2M
$11M
$6.2M
$6.6M
$8.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$35.9M−$105M
FY24$35.6M−$105.3M
FY23$20.8M−$132.5M
FY22$31.1M−$128.2M
FY21$45.8M−$83.9M
FY20-−$66.3M
FY19-−$34.1M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−800%−600%−400%−200%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−320.5%−292.1%
FY24−336.1%−296%
FY23−669.8%−638.3%
FY22−416.6%−412.2%
FY21−179.4%−183.2%
FY20--
FY19--
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50M$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$99.3M
FY24−$65.3M
FY23−$108.5M
FY22−$111.4M
FY21−$88.2M
FY20−$67.9M
FY19$54.3M
FY18-
Returned to shareholdersDividends paid and shares bought back
$0$50K$100K$150K$200KFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$193K
FY24$194K
FY23$110K
FY22$0
FY21-
FY20$194K
FY19$30K
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • C4 Therapeutics (United States)
  • Healthcare median
−800%−600%−400%−200%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearC4 Therapeutics (United States)Healthcare median
FY25−292.1%−30.6%
FY24−296%−47%
FY23−638.3%−58%
FY22−412.2%−80.4%
FY21−183.2%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%